Parul Tandon
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Parul Tandon has a total of 167 co-authors. Here are the top co-authors by number of shared publications:
- Vivian Huang
Mount Sinai Centre for Inflammatory Bowel Disease , Toronto, Ontario
12 shared publications - Charles N. Bernstein
University of Manitoba IBD Clinical and Research Centre, University of Manitoba, Winnipeg, Canada
11 shared publications - Eric I. Benchimol
Division of Gastroenterology, Hepatology and Nutrition, The Hospital for Sick Children (SickKids), Toronto, Canada; ICES, Toronto, Canada; Child Health Evaluative Sciences, SickKids Research Institute, The Hospital for Sick Children (SickKids), Toronto, Canada; Department of Paediatrics, University of Toronto, Toronto, Canada; Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, Canada
11 shared publications Alain Bitton
Division of Gastroenterology and Hepatology, McGill University Health Centre IBD Centre, McGill University , Montréal, Quebec , Canada
10 shared publications- Gilaad G. Kaplan
Departments of Medicine and Community Health Sciences, University of Calgary, Calgary, Canada
10 shared publications - M. Ellen Kuenzig
SickKids Inflammatory Bowel Disease Centre, Division of Gastroenterology, Hepatology and Nutrition, The Hospital for Sick Children (SickKids) , Toronto, ON
10 shared publications
Latest Publications
- Open Access
- 8 September 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (18) , 6961
Racial, Ethnic, and Immigration-Related Disparities Across the Gastrointestinal Care Continuum: A Scoping Review
Background: Gastrointestinal (GI) diseases contribute substantially to healthcare utilization and chronic disease burden through recurrent symptoms, ongoing specialist care, and diagnostic evaluation. However, disparities related to race, ethnicity, and immigration status may arise at multiple points along the GI care continuum, and their association with access, diagnosis, treatment, and outcomes remains incompletely characterized. This scoping review synthesizes evidence on these differences in GI healthcare delivery. Methods: MEDLINE and Embase were searched from 1 January 2000 to 17 June 2025, with supplementary grey literature searches of relevant GI, liver, surgical, and endoscopic society websites. Findings were synthesized thematically due to heterogeneity in study design, populations, outcomes, and reporting. Results: Seventy-four studies were included across various GI diseases, including inflammatory bowel disease, hepatobiliary disease, esophageal disorders, and liver transplantation. Differences in care were reported across multiple care stages, including specialist access; diagnostic and treatment delays; use of medical, procedural, and surgical therapies; emergency care reliance; and transplant access and outcomes. Findings were, however, heterogeneous, with some studies reporting no differences or higher utilization among minority groups. Conclusions: Racial, ethnic, and immigration-related differences are reported across GI care pathways. Future research should identify modifiable factors that may lead to practice-changing interventions that will improve timely, equitable, longitudinal care.
- 8 September 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (18) , 6961
Open AccessRacial, Ethnic, and Immigration-Related Disparities Across the Gastrointestinal Care Continuum: A Scoping Review
Background: Gastrointestinal (GI) diseases contribute substantially to healthcare utilization and chronic disease burden through recurrent symptoms, ongoing specialist care, and diagnostic evaluation. However, disparities related to race, ethnicity, and immigration status may arise at multiple points along the GI care continuum, and their association with access, diagnosis, treatment, and outcomes remains incompletely characterized. This scoping review synthesizes evidence on these differences in GI healthcare delivery. Methods: MEDLINE and Embase were searched from 1 January 2000 to 17 June 2025, with supplementary grey literature searches of relevant GI, liver, surgical, and endoscopic society websites. Findings were synthesized thematically due to heterogeneity in study design, populations, outcomes, and reporting. Results: Seventy-four studies were included across various GI diseases, including inflammatory bowel disease, hepatobiliary disease, esophageal disorders, and liver transplantation. Differences in care were reported across multiple care stages, including specialist access; diagnostic and treatment delays; use of medical, procedural, and surgical therapies; emergency care reliance; and transplant access and outcomes. Findings were, however, heterogeneous, with some studies reporting no differences or higher utilization among minority groups. Conclusions: Racial, ethnic, and immigration-related differences are reported across GI care pathways. Future research should identify modifiable factors that may lead to practice-changing interventions that will improve timely, equitable, longitudinal care.
- Open Access
- 6 August 2026
- Published by MDPI AG in Healthcare
- Vol. 14 (15) , 2425
Estimated Travel-Related CO2 Emissions Avoided Through Virtual Care for Inflammatory Bowel Disease Patients in Remote Regions of Ontario, Canada
Background/Objectives: Inflammatory bowel disease (IBD) requires frequent specialist follow-up, yet patients in remote areas face significant geographic barriers to care. Healthcare delivery also contributes substantially to greenhouse gas (GHG) emissions, with patient travel a major source. The Promoting Access and Care through Centres of Excellence (PACE) virtual care program was designed to improve access for IBD patients in underserved regions of Ontario. This study estimated travel-related carbon dioxide (CO2) emissions potentially avoided. Methods: A retrospective cohort study was conducted using the PACE registry at the Mount Sinai Hospital IBD Centre between June 2016 and October 2024. Adults with Crohn’s disease, ulcerative colitis, or IBD-unclassified residing ≥100 km from the Centre and completing ≥1 virtual visit were included. Two-way travel distance avoided was calculated using Google Maps, adjusting for any travel to local facilities. Carbon emissions were estimated using a composite base-case factor of 260 g CO2/km with predefined sensitivity analyses covering alternative vehicle-mix and transport scenarios. Results: Among 389 IBD patients, 2222 virtual visits were completed. The mean (±SD) two-way distance avoided per visit was 843 ± 812 km, corresponding to 219 ± 211 kg CO2 per visit. The mean cumulative reduction per patient was 1252 ± 2245 kg CO2, totalling 487,104 kg (487 tonnes) over eight years. Conclusions: The PACE program was associated with substantial estimated reductions in travel-related CO2 emissions for IBD patients in remote Ontario, with results robust across vehicle mix and transport assumptions. Virtual care may offer a scalable pathway advancing both equitable access and healthcare-sector decarbonization.
- 6 August 2026
- Published by MDPI AG in Healthcare
- Vol. 14 (15) , 2425
Open AccessEstimated Travel-Related CO2 Emissions Avoided Through Virtual Care for Inflammatory Bowel Disease Patients in Remote Regions of Ontario, Canada
Background/Objectives: Inflammatory bowel disease (IBD) requires frequent specialist follow-up, yet patients in remote areas face significant geographic barriers to care. Healthcare delivery also contributes substantially to greenhouse gas (GHG) emissions, with patient travel a major source. The Promoting Access and Care through Centres of Excellence (PACE) virtual care program was designed to improve access for IBD patients in underserved regions of Ontario. This study estimated travel-related carbon dioxide (CO2) emissions potentially avoided. Methods: A retrospective cohort study was conducted using the PACE registry at the Mount Sinai Hospital IBD Centre between June 2016 and October 2024. Adults with Crohn’s disease, ulcerative colitis, or IBD-unclassified residing ≥100 km from the Centre and completing ≥1 virtual visit were included. Two-way travel distance avoided was calculated using Google Maps, adjusting for any travel to local facilities. Carbon emissions were estimated using a composite base-case factor of 260 g CO2/km with predefined sensitivity analyses covering alternative vehicle-mix and transport scenarios. Results: Among 389 IBD patients, 2222 virtual visits were completed. The mean (±SD) two-way distance avoided per visit was 843 ± 812 km, corresponding to 219 ± 211 kg CO2 per visit. The mean cumulative reduction per patient was 1252 ± 2245 kg CO2, totalling 487,104 kg (487 tonnes) over eight years. Conclusions: The PACE program was associated with substantial estimated reductions in travel-related CO2 emissions for IBD patients in remote Ontario, with results robust across vehicle mix and transport assumptions. Virtual care may offer a scalable pathway advancing both equitable access and healthcare-sector decarbonization.
- Open Access
- 12 June 2026
- Published by Elsevier in Clinics and Research in Hepatology and Gastroenterology
- Vol. 50 (7) , 102869
Using clinical factors to predict treatment outcomes and health-care utilization in Crohn’s disease patients initiating advanced therapies
- 12 June 2026
- Published by Elsevier in Clinics and Research in Hepatology and Gastroenterology
- Vol. 50 (7) , 102869
Open AccessUsing clinical factors to predict treatment outcomes and health-care utilization in Crohn’s disease patients initiating advanced therapies
- Open Access
- 3 June 2026
- Published by Oxford University Press (OUP) in Crohn’s & Colitis 360
- Vol. 8 (3)
Relationship between pregnancy, delivery, and ileal pouch-anal anastomosis for inflammatory bowel disease: a retrospective chart review
Background: Pregnant women with inflammatory bowel disease (IBD) and an ileal pouch-anal anastomosis (IPAA) often receive conflicting medical advice regarding mode of delivery, and healthcare providers may have diverging opinions. Cesarean delivery is commonly performed out of concern of injuring the anal sphincter during vaginal delivery, causing poorer long-term pouch function. This study aims to describe rates of vaginal and cesarean delivery, complication rates and assess the impact of pregnancy and delivery on pouch function for patients with IBD and an IPAA. Methods: This retrospective single center chart review study included patients with IBD, an IPAA, and a completed pregnancy between January 1, 2002 and February 1, 2021. Patient demographics, IBD diagnosis, IPAA procedure details, mode of delivery and complications, and pouch function surrounding pregnancy were compared using descriptive statistics. Results: Sixty-two patients completed 85 pregnancies. Eighty-one percent of pregnancies had a cesarean delivery (69/85); of these, 51 (73.9%) were planned elective cesareans while 18 (26.1%) were urgent. Among the planned elective cesareans, 51.6% were indicated to prevent injury to the anal sphincter and preserve pelvic pouch function. Immediate risks of cesarean and vaginal delivery were similar to the general population. Rates of delivery intervention with episiotomy were high (50% of vaginal deliveries). All vaginal deliveries took place in the later 10 years of the study period. Pouch function postpartum was infrequently documented. Conclusions: Pregnant patients with IBD and an IPAA frequently had a cesarean delivery, often to avoid anal sphincter injury from vaginal delivery and preserve pelvic pouch function. Delivery practices shifted in the past 10 years to include vaginal delivery, likely reflecting an increased perceived safety of this delivery mode.
- 3 June 2026
- Published by Oxford University Press (OUP) in Crohn’s & Colitis 360
- Vol. 8 (3)
Open AccessRelationship between pregnancy, delivery, and ileal pouch-anal anastomosis for inflammatory bowel disease: a retrospective chart review
Background: Pregnant women with inflammatory bowel disease (IBD) and an ileal pouch-anal anastomosis (IPAA) often receive conflicting medical advice regarding mode of delivery, and healthcare providers may have diverging opinions. Cesarean delivery is commonly performed out of concern of injuring the anal sphincter during vaginal delivery, causing poorer long-term pouch function. This study aims to describe rates of vaginal and cesarean delivery, complication rates and assess the impact of pregnancy and delivery on pouch function for patients with IBD and an IPAA. Methods: This retrospective single center chart review study included patients with IBD, an IPAA, and a completed pregnancy between January 1, 2002 and February 1, 2021. Patient demographics, IBD diagnosis, IPAA procedure details, mode of delivery and complications, and pouch function surrounding pregnancy were compared using descriptive statistics. Results: Sixty-two patients completed 85 pregnancies. Eighty-one percent of pregnancies had a cesarean delivery (69/85); of these, 51 (73.9%) were planned elective cesareans while 18 (26.1%) were urgent. Among the planned elective cesareans, 51.6% were indicated to prevent injury to the anal sphincter and preserve pelvic pouch function. Immediate risks of cesarean and vaginal delivery were similar to the general population. Rates of delivery intervention with episiotomy were high (50% of vaginal deliveries). All vaginal deliveries took place in the later 10 years of the study period. Pouch function postpartum was infrequently documented. Conclusions: Pregnant patients with IBD and an IPAA frequently had a cesarean delivery, often to avoid anal sphincter injury from vaginal delivery and preserve pelvic pouch function. Delivery practices shifted in the past 10 years to include vaginal delivery, likely reflecting an increased perceived safety of this delivery mode.
- Open Access
- 9 November 2025
- Published by Oxford University Press (OUP) in Journal of the Canadian Association of Gastroenterology
- Vol. 9 (1) , 24-29
Patterns of specialist healthcare delivery among inflammatory bowel disease patients in response to the COVID-19 pandemic in Ontario: a population-based study
Background: Access to inflammatory bowel diseases (IBD) specialist care is a predictor of health outcomes. We sought to characterize the impact of the pandemic on patterns of IBD healthcare delivery and whether it compromised overall access to care. Methods: We identified adults with an IBD diagnosis residing in Ontario between 2016 and 2021 using administrative data at ICES. We determined quarterly rates of in-person and virtual IBD specialist visits and stratified that by regions with high and low access to IBD specialists. We stratified our analyses into 3 periods: pre-COVID, immediate COVID, and maintenance COVID. We performed interrupted time series analysis to assess for time trends. Results: During the immediate COVID phase, there was a 69% relative quarterly decline in in-person IBD specialist visits with a concurrent 591% relative quarterly rise in rates of virtual visits. Entering the COVID maintenance phase, there was a 7% quarterly relative decline in the rate of in-person visits, and a 7% and 4% quarterly relative increases in the rates of virtual and total IBD specialist visits, respectively. Pre-pandemic, IBD patients residing in regions with high specialist access had a 16% higher rate of visits than those in low-access regions. During the COVID maintenance phase, the disparity was reduced to 12%. Conclusions: During the COVID-19 pandemic, the rapid transition from in-person to virtual IBD specialist care led to a slight increase in overall IBD visits. There was also a small decrease in the gap in rates of IBD specialist visits between high- and low-access regions.
- 9 November 2025
- Published by Oxford University Press (OUP) in Journal of the Canadian Association of Gastroenterology
- Vol. 9 (1) , 24-29
Open AccessPatterns of specialist healthcare delivery among inflammatory bowel disease patients in response to the COVID-19 pandemic in Ontario: a population-based study
Background: Access to inflammatory bowel diseases (IBD) specialist care is a predictor of health outcomes. We sought to characterize the impact of the pandemic on patterns of IBD healthcare delivery and whether it compromised overall access to care. Methods: We identified adults with an IBD diagnosis residing in Ontario between 2016 and 2021 using administrative data at ICES. We determined quarterly rates of in-person and virtual IBD specialist visits and stratified that by regions with high and low access to IBD specialists. We stratified our analyses into 3 periods: pre-COVID, immediate COVID, and maintenance COVID. We performed interrupted time series analysis to assess for time trends. Results: During the immediate COVID phase, there was a 69% relative quarterly decline in in-person IBD specialist visits with a concurrent 591% relative quarterly rise in rates of virtual visits. Entering the COVID maintenance phase, there was a 7% quarterly relative decline in the rate of in-person visits, and a 7% and 4% quarterly relative increases in the rates of virtual and total IBD specialist visits, respectively. Pre-pandemic, IBD patients residing in regions with high specialist access had a 16% higher rate of visits than those in low-access regions. During the COVID maintenance phase, the disparity was reduced to 12%. Conclusions: During the COVID-19 pandemic, the rapid transition from in-person to virtual IBD specialist care led to a slight increase in overall IBD visits. There was also a small decrease in the gap in rates of IBD specialist visits between high- and low-access regions.
- Open Access
- 23 September 2025
- Published by Catalytic Health in Canadian IBD Today
- p. 23–27
Cytomegalovirus Colitis in Inflammatory Bowel Disease The Eternal Debate: Foe or Innocent Bystander?
Key Takeaways: • The prevalence of CMV infection among patients with IBD ranges from 2 to 29%, with a higher prevalence in those with UC compared to CD. • Immunohistochemistry and tissue PCR, or both, are the recommended tests for diagnosing active CMV colitis. • CMV may be an active pathogenic participant in cases with a high density of CMV and severe disease activity. Thus, we recommend testing for CMV colitis in patients with a severe inflammatory burden who are not responding to conventional IBD therapy. • Patients with low CMV viral burden can likely be treated with immunosuppression alone, while patients with high viral density or medically refractory disease should be treated with antiviral therapy.
- 23 September 2025
- Published by Catalytic Health in Canadian IBD Today
- p. 23–27
Open AccessCytomegalovirus Colitis in Inflammatory Bowel Disease The Eternal Debate: Foe or Innocent Bystander?
Key Takeaways: • The prevalence of CMV infection among patients with IBD ranges from 2 to 29%, with a higher prevalence in those with UC compared to CD. • Immunohistochemistry and tissue PCR, or both, are the recommended tests for diagnosing active CMV colitis. • CMV may be an active pathogenic participant in cases with a high density of CMV and severe disease activity. Thus, we recommend testing for CMV colitis in patients with a severe inflammatory burden who are not responding to conventional IBD therapy. • Patients with low CMV viral burden can likely be treated with immunosuppression alone, while patients with high viral density or medically refractory disease should be treated with antiviral therapy.
- Open Access
- 3 September 2025
- Published by Oxford University Press (OUP) in Journal of the Canadian Association of Gastroenterology
- Vol. 8 (5) , 163-178
Infections in primary sclerosing cholangitis and inflammatory bowel disease: a systematic review and meta-analysis
Purpose: Primary sclerosing cholangitis (PSC) is a cholestatic liver disease that frequently coexists with inflammatory bowel disease (IBD). The risk of infections in patients with concurrent PSC-IBD remains unclear. The aim of this study was to identify the event rate of infections and associated risk factors in PSC-IBD patients. Methods: MEDLINE, Embase, and the Cochrane Central Register of Controlled Trials were searched from inception to September 12, 2024 for studies examining event rate or risk factors for infection in patients with PSC-IBD. The primary outcome was the event rate of all-cause and site-specific infections as well as infection-related mortality. The secondary outcome was risk factors for infection. Random-effects models were used to calculate pooled odds ratios (OR) with 95% confidence intervals (CI) comparing the event rate of all-cause infections in PSC-IBD patients to those with just PSC and just IBD. I2 values more than 50% suggested substantial heterogeneity. Results: Eighty-one studies were included. The pooled event rate of all-cause infections in patients with PSC-IBD was 25.1% (95% CI, 17.0%-33.2%, I2 = 99.2%). PSC-IBD patients had significantly increased odds of all-cause infection (OR 3.67, 95% CI, 2.07-6.52, I2 = 41.9%), sepsis (OR 3.35, 95% CI, 2.29-4.91, I2 = 9.1%), and infection-related mortality (OR 11.25, 95% CI, 2.03-62.37, I2 = 0) compared to those with IBD but not those with PSC. Conclusion: Patients with PSC-IBD appear to be at increased risk of all-cause infection, sepsis, and mortality compared to those with IBD alone.
- 3 September 2025
- Published by Oxford University Press (OUP) in Journal of the Canadian Association of Gastroenterology
- Vol. 8 (5) , 163-178
Open AccessInfections in primary sclerosing cholangitis and inflammatory bowel disease: a systematic review and meta-analysis
Purpose: Primary sclerosing cholangitis (PSC) is a cholestatic liver disease that frequently coexists with inflammatory bowel disease (IBD). The risk of infections in patients with concurrent PSC-IBD remains unclear. The aim of this study was to identify the event rate of infections and associated risk factors in PSC-IBD patients. Methods: MEDLINE, Embase, and the Cochrane Central Register of Controlled Trials were searched from inception to September 12, 2024 for studies examining event rate or risk factors for infection in patients with PSC-IBD. The primary outcome was the event rate of all-cause and site-specific infections as well as infection-related mortality. The secondary outcome was risk factors for infection. Random-effects models were used to calculate pooled odds ratios (OR) with 95% confidence intervals (CI) comparing the event rate of all-cause infections in PSC-IBD patients to those with just PSC and just IBD. I2 values more than 50% suggested substantial heterogeneity. Results: Eighty-one studies were included. The pooled event rate of all-cause infections in patients with PSC-IBD was 25.1% (95% CI, 17.0%-33.2%, I2 = 99.2%). PSC-IBD patients had significantly increased odds of all-cause infection (OR 3.67, 95% CI, 2.07-6.52, I2 = 41.9%), sepsis (OR 3.35, 95% CI, 2.29-4.91, I2 = 9.1%), and infection-related mortality (OR 11.25, 95% CI, 2.03-62.37, I2 = 0) compared to those with IBD but not those with PSC. Conclusion: Patients with PSC-IBD appear to be at increased risk of all-cause infection, sepsis, and mortality compared to those with IBD alone.
- 8 July 2025
- Published by Oxford University Press (OUP) in Inflammatory Bowel Diseases
- Vol. 31 (10) , 2945-2946
Response to “The Association of Inflammatory Bowel Disease and Eosinophilic Esophagitis: True Link or Surveillance Artifact?
- 8 July 2025
- Published by Oxford University Press (OUP) in Inflammatory Bowel Diseases
- Vol. 31 (10) , 2945-2946
Response to “The Association of Inflammatory Bowel Disease and Eosinophilic Esophagitis: True Link or Surveillance Artifact?
- 28 June 2025
- Published by Oxford University Press (OUP) in Inflammatory Bowel Diseases
- Vol. 31 (11) , 2955-2964
Unraveling Genetic Versus Environmental Factors Determining Disease Course in Inflammatory Bowel Diseases: A Population-Based Cohort Study in First- and Second-Generation Immigrants
Background: Inflammatory bowel diseases (IBD) incidence in immigrants approximates that of the host country in progressive generations but less is known about their disease outcome. We investigate how the immigrant generation affects IBD outcomes. Methods: In this population-based cohort study, the risks of first IBD-related hospitalization, first IBD-related surgery, need for advanced therapies, and perianal disease were compared between first- and second-generation immigrants (stratified into Western/non-Western) and native Danes, using Cox proportional hazard regression to estimate adjusted hazard ratios (aHRs), correcting for sex, age at IBD diagnosis, and calendar year of IBD diagnosis. Results: First-generation immigrants had lower risk of IBD-related surgery (aHRWestern 0.89; 95% confidence interval [CI] 0.75–1.05, aHRnon-Western 0.79; 95% CI, 0.67–0.92) and advanced therapy (aHRWestern 0.87; 95% CI, 0.77–0.99, aHRnon-Western 0.83; 95% CI, 0.74–0.94) than native Danes, whereas second-generation immigrants resembled native Danes. However, second-generation immigrants had higher risk of hospitalization than native Danes (aHRWestern 1.28; 95% CI, 1.05–1.55, aHRnon-Western 1.40; 95% CI, 1.28–1.54), whereas in first-generation immigrants this was only observed in non-Western ulcerative colitis patients (aHR 1.19; 95% CI, 1.08–1.32). Across both generations, non-Western immigrants had higher risk of perianal disease (Crohn’s disease: aHRfirst-generation 1.55; 95% CI, 1.25–1.92; aHRsecond-generation 1.58; 95% CI, 1.25–2.01). Conclusions: Disease outcomes change across immigrant generations, pointing to environmental factors possibly impacting disease course, which needs further investigation. In contrast, non-Western immigrants were shown to have more perianal disease in both generations, suggesting a genetic susceptibility for this debilitating phenotype.
- 28 June 2025
- Published by Oxford University Press (OUP) in Inflammatory Bowel Diseases
- Vol. 31 (11) , 2955-2964
Unraveling Genetic Versus Environmental Factors Determining Disease Course in Inflammatory Bowel Diseases: A Population-Based Cohort Study in First- and Second-Generation Immigrants
Background: Inflammatory bowel diseases (IBD) incidence in immigrants approximates that of the host country in progressive generations but less is known about their disease outcome. We investigate how the immigrant generation affects IBD outcomes. Methods: In this population-based cohort study, the risks of first IBD-related hospitalization, first IBD-related surgery, need for advanced therapies, and perianal disease were compared between first- and second-generation immigrants (stratified into Western/non-Western) and native Danes, using Cox proportional hazard regression to estimate adjusted hazard ratios (aHRs), correcting for sex, age at IBD diagnosis, and calendar year of IBD diagnosis. Results: First-generation immigrants had lower risk of IBD-related surgery (aHRWestern 0.89; 95% confidence interval [CI] 0.75–1.05, aHRnon-Western 0.79; 95% CI, 0.67–0.92) and advanced therapy (aHRWestern 0.87; 95% CI, 0.77–0.99, aHRnon-Western 0.83; 95% CI, 0.74–0.94) than native Danes, whereas second-generation immigrants resembled native Danes. However, second-generation immigrants had higher risk of hospitalization than native Danes (aHRWestern 1.28; 95% CI, 1.05–1.55, aHRnon-Western 1.40; 95% CI, 1.28–1.54), whereas in first-generation immigrants this was only observed in non-Western ulcerative colitis patients (aHR 1.19; 95% CI, 1.08–1.32). Across both generations, non-Western immigrants had higher risk of perianal disease (Crohn’s disease: aHRfirst-generation 1.55; 95% CI, 1.25–1.92; aHRsecond-generation 1.58; 95% CI, 1.25–2.01). Conclusions: Disease outcomes change across immigrant generations, pointing to environmental factors possibly impacting disease course, which needs further investigation. In contrast, non-Western immigrants were shown to have more perianal disease in both generations, suggesting a genetic susceptibility for this debilitating phenotype.
- Open Access
- 4 June 2025
- Published by Oxford University Press (OUP) in Inflammatory Bowel Diseases
- Vol. 31 (10) , 2895-2906
The Association of Inflammatory Bowel Disease and Eosinophilic Esophagitis: A Systematic Review and Meta-analysis
Background: The association between inflammatory bowel disease (IBD) and eosinophilic esophagitis (EoE) remains unclear. We aimed to perform a systematic review and meta-analysis on the association between EoE, IBD, and other immune-mediated inflammatory diseases. Methods: A systematic literature search was conducted in Ovid MEDLINE, Ovid Embase, and the Cochrane Central Register of Controlled Trials (Ovid) from inception to July 2023. The primary outcome was to compare the frequency of an EoE diagnosis in IBD and other immune-mediated inflammatory disease processes versus control populations. Where pooled analysis was possible, we reported odds ratios (ORs) with 95% confidence intervals (CIs). I2 values were used to report heterogeneity, with values >50% suggesting substantial heterogeneity. Results: We identified 2612 eligible studies, of which 38 studies were included. A diagnosis of EoE was significantly greater in patients with IBD compared to the general population (OR 3.9; 95% CI, 2.6-5.9 [I2 = 99.5%]). There was no significant increase in EoE in patients with ulcerative colitis compared to Crohn’s disease (OR 1.0; 95% CI, 0.7-1.3 [I2 = 88.7%]). EoE was also significantly increased in patients with atopic dermatitis (OR 2.4; 95% CI, 1.9-3.1 3 [I2 = 70.4%]) compared to those without atopic dermatitis. Conclusions: Both IBD and atopic dermatitis were associated with an increased odds of EoE diagnosis. Further research is needed to determine the underlying mechanisms behind these potential associations.
- 4 June 2025
- Published by Oxford University Press (OUP) in Inflammatory Bowel Diseases
- Vol. 31 (10) , 2895-2906
Open AccessThe Association of Inflammatory Bowel Disease and Eosinophilic Esophagitis: A Systematic Review and Meta-analysis
Background: The association between inflammatory bowel disease (IBD) and eosinophilic esophagitis (EoE) remains unclear. We aimed to perform a systematic review and meta-analysis on the association between EoE, IBD, and other immune-mediated inflammatory diseases. Methods: A systematic literature search was conducted in Ovid MEDLINE, Ovid Embase, and the Cochrane Central Register of Controlled Trials (Ovid) from inception to July 2023. The primary outcome was to compare the frequency of an EoE diagnosis in IBD and other immune-mediated inflammatory disease processes versus control populations. Where pooled analysis was possible, we reported odds ratios (ORs) with 95% confidence intervals (CIs). I2 values were used to report heterogeneity, with values >50% suggesting substantial heterogeneity. Results: We identified 2612 eligible studies, of which 38 studies were included. A diagnosis of EoE was significantly greater in patients with IBD compared to the general population (OR 3.9; 95% CI, 2.6-5.9 [I2 = 99.5%]). There was no significant increase in EoE in patients with ulcerative colitis compared to Crohn’s disease (OR 1.0; 95% CI, 0.7-1.3 [I2 = 88.7%]). EoE was also significantly increased in patients with atopic dermatitis (OR 2.4; 95% CI, 1.9-3.1 3 [I2 = 70.4%]) compared to those without atopic dermatitis. Conclusions: Both IBD and atopic dermatitis were associated with an increased odds of EoE diagnosis. Further research is needed to determine the underlying mechanisms behind these potential associations.